April 6, 2017 / 11:15 AM / 4 months ago

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

April 6 (Reuters) - AcelRx Pharmaceuticals Inc:

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

* AcelRx Pharma -DSUVIA may have benefit as non-invasive analgesic modality in certain settings requiring short-term treatment of acute moderate-to-severe pain

* AcelRx Pharmaceuticals Inc- no statistical separation was observed between active and placebo-controlled groups for dsuvia

* AcelRx Pharmaceuticals - in emergency department study, DSUVIA resulted in a 3-point reduction in pain intensity within 60 minutes of administration Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below